BIO Digital Sample Attendee List As of June 5, 2020
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Immunotherapy and Chimeric Antigen Receptor T-Cell Therapy in Hepatocellular Carcinoma
11 Review Article Page 1 of 11 Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma Pedro Luiz Serrano Uson Junior1#, Alex J. Liu2#, Mohamad Bassam Sonbol1, Mitesh J. Borad1, Tanios S. Bekaii-Saab1 1Mayo Clinic Cancer Center, Phoenix, AZ, USA; 2Mayo Clinic Internal Medicine Residency, Phoenix, AZ, USA Contributions: (I) Conception and design: PLS Uson Junior, AJ Liu, MB Sonbol; (II) Administrative support: MJ Borad, TS Bekaii-Saab; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These authors contributed equally to this work. Correspondence to: Tanios S. Bekaii-Saab, MD. Professor of Medicine, Division of Hematology and Medical Oncology, Mayo Clinic, 5881 East Mayo Blvd, Phoenix, Arizona 85054, USA. Email: [email protected]. Abstract: Advanced hepatocellular carcinoma (HCC) is a deadly disease. With increasing incidence of new cases over the last years multiple efforts have been made to ameliorate survival and quality of life. Recent advances in understanding the tumor microenvironment and cancer immune evasion led to development of potent immune therapies targeting programmed death-ligand-1 (PD-L1), programmed cell death protein 1 (PD-1) and anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4). Early clinical studies highlighted the activity and synergism of checkpoint inhibitors with antiangiogenic drugs, including anti- vascular endothelial growth factor (VEGF) antibodies and multi-tyrosine kinase inhibitors. Most recently, the combination of bevacizumab and atezolizumab improved survival compared to sorafenib in the treatment of advanced HCC on first-line therapy in a randomized phase III trial and now is considered the standard of care. -
Outlaw: Wilderness and Exile in Old and Middle
THE ‘BESTLI’ OUTLAW: WILDERNESS AND EXILE IN OLD AND MIDDLE ENGLISH LITERATURE A Dissertation Presented to the Faculty of the Graduate School of Cornell University In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Sarah Michelle Haughey August 2011 © 2011 Sarah Michelle Haughey THE ‘BESTLI’ OUTLAW: WILDERNESS AND EXILE IN OLD AND MIDDLE ENGLISH LITERATURE Sarah Michelle Haughey, Ph. D. Cornell University 2011 This dissertation, The ‘Bestli’ Outlaw: Wilderness and Exile in Old and Middle English Literature explores the reasons for the survival of the beast-like outlaw, a transgressive figure who highlights tensions in normative definitions of human and natural, which came to represent both the fears and the desires of a people in a state of constant negotiation with the land they inhabited. Although the outlaw’s shelter in the wilderness changed dramatically from the dense and menacing forests of Anglo-Saxon England to the bright, known, and mapped greenwood of the late outlaw romances and ballads, the outlaw remained strongly animalistic, other, and liminal, in strong contrast to premodern notions of what it meant to be human and civilized. I argue that outlaw narratives become particularly popular and poignant at moments of national political and ecological crisis—as they did during the Viking attacks of the Anglo-Saxon period, the epoch of intense natural change following the Norman Conquest, and the beginning of the market revolution at the end of the Middle Ages. Figures like the Anglo-Saxon resistance fighter Hereward, the exiled Marcher lord Fulk Fitz Waryn, and the brutal yet courtly Gamelyn and Robin Hood, represent a lost England imagined as pristine and forested. -
View a Copy of This Licence, Visit Tivecommons.Org/Licenses/By/4.0
Katakami et al. Cardiovasc Diabetol (2020) 19:110 https://doi.org/10.1186/s12933-020-01079-4 Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Tofoglifozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study Naoto Katakami1,2* , Tomoya Mita3, Hidenori Yoshii4, Toshihiko Shiraiwa5, Tetsuyuki Yasuda6, Yosuke Okada7, Keiichi Torimoto7, Yutaka Umayahara8, Hideaki Kaneto9, Takeshi Osonoi10, Tsunehiko Yamamoto11, Nobuichi Kuribayashi12, Kazuhisa Maeda13, Hiroki Yokoyama14, Keisuke Kosugi15, Kentaro Ohtoshi16, Isao Hayashi17, Satoru Sumitani18, Mamiko Tsugawa19, Kayoko Ryomoto20, Hideki Taki21, Tadashi Nakamura22, Satoshi Kawashima23, Yasunori Sato24, Hirotaka Watada3 and Iichiro Shimomura1 on behalf of the UTOPIA study investigators Abstract Background: This study aimed to investigate the preventive efects of tofoglifozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disease (CVD) by monitoring carotid intima-media thickness (IMT). Methods: This prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group, comparative study included 340 subjects with T2DM and no history of apparent CVD recruited at 24 clinical units. Subjects were randomly allocated to either the tofoglifozin treatment group (n 169) or conventional treatment group using drugs other than SGLT2 inhibitors (n 171). Primary outcomes were changes= in mean and maximum common carotid IMT measured by echography during= a 104-week treatment period. Results: In a mixed-efects model for repeated measures, the mean IMT of the common carotid artery (mean- IMT-CCA), along with the right and left maximum IMT of the CCA (max-IMT-CCA), signifcantly declined in both the tofoglifozin ( 0.132 mm, SE 0.007; 0.163 mm, SE 0.013; 0.170 mm, SE 0.020, respectively) and the control group ( 0.140 mm,− SE 0.006; 0.190 mm,− SE 0.012; 0.190 mm,− SE 0.020, respectively). -
Updated May 26, 2021 Cross-Border Industry Partnerships on COVID-19 Vaccines and Therapeutics Vaccines • Curevac O Celonic Wi
Updated May 26, 2021 Cross-Border Industry Partnerships on COVID-19 Vaccines and Therapeutics Vaccines • CureVac o Celonic will manufacture 100 million doses of CureVac’s vaccine at its plant in Heidelberg, Germany, providing bulk substance for 50 million doses by the end of 2021. (press release) o Novartis will manufacture CureVac’s vaccine. (press release) o GlaxoSmithKline plc and CureVac N.V. announced a new €150m collaboration, building on their existing relationship, to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine. (press release) o Rentschler Biopharma SE will manufacture CureVac’s vaccine. (press release) o Bayer will support the further development, supply and key territory operations of CureVac’s vaccine candidate. (press release) o Fareva will dedicate a manufacturing plant in France to the fill and finish of CureVac’s vaccine. (press release) o Wacker Chemie AG will manufacture CureVac’s vaccine candidate at its Amsterdam site. (press release) o CureVac will collaborate with Tesla Grohmann Automation to develop an RNA printer that works like a mini-factory and can produce such drugs automatically. (press release) • Moderna o Samsung Biologics will provide large scale, commercial fill-finish manufacturing for Moderna’s vaccine in South Korea. (press release) o Baxter International will provide fill/finish services and supply packaging for Moderna. (press release) o Sanofi will manufacture 200 million doses of Moderna’s COVID-19 vaccine starting in September 2021. (press release) o Rovi will produce bulk substance for Moderna’s COVID-19 vaccine, expanding an agreement between the companies. -
Fraternization: Time for a Rational Department of Defense Standard
Volume 135 Winter 1992 MILITARY LAW REVIEW ARTICLES IS THE DOCTRISE OF EQIXABLE TOLLISG APPLICABLE TO THE LIYITATIOSSPERIODS IS THE FEDERAL TORT CLAIMS ACT? . , . , . , . , . , , . , . , , , . , , . , . , . , , . , . , . , , , , . , , , , , . , . Richard Parker CRIMISALL IABILITY CSDERTHE USIFORMC ODE OF MILITARY JUSTICE FOR SEXL.4L RELATIOSS DCRISGP SYCHOTHERAPY . , . , . , . , . , . , . , , . , . , . , . , . , . , . , . , , . Captain Jody M. Prescott Dr. Matthew G. Snow FRATERSIZATION:TIME FOR A RATIOS DEPARTMENT OF UEFESSE STANDARD Major David S. Jonas FREEDOM OF ~AVIG.4TION.4SD THE BLACK SEA BCMPINGISCIDENT: How "INSOCEST"M UST ISNOCENTPASSAGE BE Lieutenant Commander John W. Rolph DETERMISING CLEASUPSTASDARDS FOR HAZARDOLS WASTE SITES , . , , . , . , . , . , . , . , . , . , . , . , . , . , Major William D. Turkula BOOK REVIEWS Charlottesville, Virginia Pamphlet HEADQUARTERS DEPARTMENT OF THE ARMY NO. 27-100-135 Washington, D.C., Winter 1992 MILITARY LAW REVIEW- VOLUME 135 The Military Law Review has been published quarterly at The Judge Advocate General’s School, US. Army, Charlottes- ville, Virginia, since 1958. The Review provides a forum for those interested in military law to share the products of their experiences and research and is designed for use by military attorneys in connection with their official duties. Writings of- fered for publication should be of direct concern and import in this area of scholarship, and preference will be given to writ- ings that have lasting value as reference materials for the mili- tary lawyer. The Review encourages frank discussion of rele- vant legislative, administrative, and judicial developments. EDITORIAL STAFF MAJOR DANIEL P. SHAVER, Editor MS. EVA F. SKINNER, Editorial Assistant SUBSCRIPTIONS: Private subscriptions may be purchased from the Superintendent of Documents, United States Govern- ment Printing Office, Washington, D.C. 20402. Publication ex- change subscriptions are available to law schools and other organizations that publish legal periodicals. -
Sillajen to Discontinue PHOCUS Trial for Advanced Liver Cancer
SillaJen to discontinue PHOCUS trial for advanced liver cancer 06 August 2019 | News | By Sonali Wankhade The PHOCUS trial is a Phase 3 clinical trial evaluating the oncolytic immunotherapy Pexa-Vec (formerly JX-594) for advanced liver cancer SillaJen, Inc., a South Korea based clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has announced that the Independent Data Monitoring Committee (IDMC) for the company's PHOCUS trial has evaluated the results of a formal pre-planned futility analysis for this study, and has recommended discontinuation of the trial. The PHOCUS trial is a Phase 3 clinical trial evaluating the oncolytic immunotherapy Pexa-Vec (formerly JX-594) for advanced liver cancer. While Pexa-Vec is generally well tolerated by patients, the interim results suggest that the study is unlikely to meet the primary objective by the time of the final analysis. This decision was not related to the safety of the investigational product. SillaJen is taking steps to notify investigators that enrollment is being stopped. SillaJen thanks the patients, caregivers and investigators involved in our clinical study and will continue to seek effective treatments for cancer patients. "The interim results are a disappointment to the company. However, SillaJen has shifted its focus toward other combination therapies that offer a more compelling and commercially viable solution to address unmet needs in liver cancer as well as other therapeutic areas," stated Dr. Eun Sang Moon, chief executive officer of SillaJen. "Other programs have continued to deliver encouraging results. The discontinuation of the study will allow us to focus on a more promising development program." The PHOCUS trial was designed to enroll 600 patients, worldwide, who had not received prior systemic treatment for their cancer, and they were randomized to one of two treatment groups: one which received Pexa-Vec followed by sorafenib and one which received sorafenib alone. -
Sorafenib in Patients with Hepatocellular Carcinoma—Results of the Observational INSIGHT Study Tom M
Published OnlineFirst July 11, 2017; DOI: 10.1158/1078-0432.CCR-16-0919 Cancer Therapy: Clinical Clinical Cancer Research Sorafenib in Patients with Hepatocellular Carcinoma—Results of the Observational INSIGHT Study Tom M. Ganten1, Rudolf E. Stauber2, Eckardt Schott3, Peter Malfertheiner4, Robert Buder5, Peter R. Galle6, Thomas Gohler€ 7, Matthias Walther8, Ronald Koschny9, and Guido Gerken10 Abstract Purpose: Sorafenib is the only currently approved systemic 13.6, D: 3.1 and A: 6.0, B: 5.5, C: 3.9, and D: 1.7 months, therapy for advanced hepatocellular carcinoma (HCC). We aimed respectively), Child–Pugh liver function (A: 17.6, B: 8.1, C: 5.6 to evaluate the safety and efficacy of sorafenib therapy in patients andA:5.3,B:3.3,C:2.5months,respectively),andperfor- with HCC under real-life conditions regarding patient, tumor mance status of the patient; however, age did not affect prog- characteristics, and any adverse events at study entry and at follow- nosis. Sorafenib-related adverse events at any grade occurred in up visits every 2 to 4 months. 64.9% of patients, with diarrhea (35.4%), hand–foot–skin Experimental Design: The current INSIGHT study is a non- reaction (16.6%), nausea (10.3%), and fatigue (11.2%) occur- interventional, prospective, multicenter, observational study per- ring most frequently. formed in 124 sites across Austria and Germany between 2008 Conclusions: Sorafenib treatment was shown to be effective in and 2014. a real-life setting, in agreement with previously reported clinical Results: Median overall survival and time to progression trial data. The therapy was found to have an acceptable safety (RECIST) were found to be dependent on baseline Barcelona profile, with predominantly mild to moderate side effects. -
SAN JUAN BASIN PUBLIC HEALTH Chief Strategy Officer
SAN JUAN BASIN PUBLIC HEALTH CLASS SPECIFICATION Chief Strategy Officer JOB FAMILY BAND/GRADE/SUBGRADE FLSA STATUS Management E81 Exempt CLASS SUMMARY: This class is the second level in a three-level Management Series. Incumbents serve as a high- level leader and strategist devoted to the management and administration of divisions and functions, reporting to the Executive Director, but working in close collaboration with the Deputy Director of Operations and the Deputy Director of Administrative Services. Incumbents apply advanced management principles to formulate, facilitate and communicate the organization’s vision, initiatives and goals. Incumbents; represent SJBPH; act as an advisor to the chief executive officer and to the Board of Health; develop and implement programs critical to SJBPH; and exercise control and supervision of multiple assigned functions and/or divisions and significant resources/assets. Within the incumbant’s designated division, managerial oversight and responsibilities cross multiple functional units within the organization. The position is responsible for program outcomes across a designated department, as assigned. Incumbents supervise management staff including overseeing and conducting performance evaluations, coordinating training; and implementing hiring, discipline and termination procedures. ESSENTIAL DUTIES: This class specification represents only the core areas of responsibilities; specific position assignments will vary depending on the needs of SJBPH. Supervises staff including overseeing and conducting -
List of Section 13F Securities
List of Section 13F Securities 1st Quarter FY 2004 Copyright (c) 2004 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of March 15, 2004, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 31, 2004. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by Section 13(f)(1) and Rule 13f-1 thereunder. -
Gedeon Richter Annual Report Gedeon Richtergedeon • Annual Report • 2011
GEDEON RICHTER ANNUAL REPORT GEDEON RICHTERGEDEON • ANNUAL REPORT • 2011 1901 2011 00Borito_annual_report_angol_2012_140_old.indd 1 3/25/12 2:29 PM Delivering quality therapy through generations 2011 01_angol_elso_resz_01_66.indd 1 3/26/12 2:23 PM 2 Contents CONTENTS Richter Group – Fact Sheet . 3 Consolidated Financial Highlights . 5 Chairman’s Statement . 7 Directors’ Report . 9 Information for Shareholders . 9 Shareholders’ Highlights . 9 Market Capitalisation . 9 Annual General Meeting . 10 Investor Relations Activities . 10 Dividend . 11 Information Regarding Richter Shares . 12 Shares in Issue . 12 Treasury Shares . 12 Registered Shareholders . 12 Share Ownership by Company Board Members . 13 Risk Management . 14 Corporate Governance . 16 Company’s Boards . 18 Board of Directors . 18 Executive Board . 21 Supervisory Committee . .22 Managing Director’s Review . 25 Operating Review . 29 Consolidated Turnover . 29 Markets – Pharmaceutical Segment . 31 Hungary . 32 International Sales . 34 European Union . 35 CIS . 37 USA . 38 Rest of the World . 38 Wholesale and Retail Activities . 39 Research and Development . 40 Female Healthcare . 42 Products . 46 Manufacturing and Supply . 50 Corporate Social Responsibility . 51 Environmental Policy . 51 Health and Safety at Work . 52 Work Health and Safety Management System . 52 Practical Implementation . 52 Community Involvement . 53 People . 54 Employees . 54 Recruitment and Individual Development . 55 Developing Leaders . 56 Remuneration and Other Employee Programmes . 56 Financial Review . 59 Key Financial Data . 59 Cost of Sales . 59 Gross Profit . 59 Operating Expenses . 60 Profit from Operations . 61 Net Financial Income . 61 Share of Profit of Associates . 62 Income Tax . 62 Profit for the Year . 62 Profit Attributable to Owners of the Parent . 62 Balance Sheet . 63 Cash Flow . -
Mckinsey Special Collection the Role of the CFO
McKinsey Special Collection The Role of the CFO Selected articles from the Strategy and Corporate Finance Practice The Role of the CFO articles Why CFOs need a bigger role in business transformations Ryan Davies and Douglas Huey April 2017 read the article Are today’s CFOs ready for tomorrow’s demands on finance? Survey December 2016 read the article Profiling the modern CFO A panel discussion October 2015 read the article Building a better partnership between finance and strategy Ankur Agrawal, Emma Bibbs and Jean-Hugues Monier October 2015 read the article The Role of the CFO McKinsey Special Collection 3 © Martin Barraud/Getty Images Why CFOs need a bigger role in business transformations CFO involvement can lead to better outcomes for organization-wide performance improvements. Ryan Davies and Douglas Huey When managers decide that a step change in that underlie a transformation. And they often have performance is desirable and achievable, they’ll an organization-wide credibility for measuring often undertake a business transformation. value creation. The way it usually works, though, is Such transformations are large-scale efforts that that CEOs sponsor transformations. A full-time run the full span of a company, challenging executive—often a chief transformation officer— the fundamentals of every organizational layer. assumes operational control, and individual That includes the most basic processes in business units take the lead on their own perfor- everything from R&D, purchasing, and production mance. That often leaves CFOs on the sidelines, to sales, marketing, and HR. And the effect on providing transaction support and auditing the earnings can be substantial—as much as 25 percent transformation’s results. -
Ranking of Stocks by Market Capitalization(As of End of Mar.2020)
Ranking of Stocks by Market Capitalization(As of End of Mar.2020) 1st Section Rank Code Issue Market Capitalization \100mil. 1 7203 TOYOTA MOTOR CORPORATION 212,127 2 9437 NTT DOCOMO,INC. 112,630 3 6861 KEYENCE CORPORATION 84,709 4 6758 SONY CORPORATION 81,786 5 9984 SoftBank Group Corp. 79,162 6 9433 KDDI CORPORATION 75,136 7 4519 CHUGAI PHARMACEUTICAL CO.,LTD. 69,960 8 9432 NIPPON TELEGRAPH AND TELEPHONE CORPORATION 68,006 9 9434 SoftBank Corp. 65,799 10 7974 Nintendo Co.,Ltd. 54,787 11 8306 Mitsubishi UFJ Financial Group,Inc. 54,735 12 4568 DAIICHI SANKYO COMPANY,LIMITED 52,707 13 4502 Takeda Pharmaceutical Company Limited 52,146 14 4661 ORIENTAL LAND CO.,LTD. 50,261 15 6098 Recruit Holdings Co.,Ltd. 47,419 16 9983 FAST RETAILING CO.,LTD. 46,873 17 7182 JAPAN POST BANK Co.,Ltd. 44,865 18 4063 Shin-Etsu Chemical Co.,Ltd. 44,707 19 7267 HONDA MOTOR CO.,LTD. 44,017 20 4452 Kao Corporation 42,560 21 6367 DAIKIN INDUSTRIES,LTD. 38,603 22 6981 Murata Manufacturing Co.,Ltd. 36,980 23 8058 Mitsubishi Corporation 36,436 24 8316 Sumitomo Mitsui Financial Group,Inc. 36,018 25 9022 Central Japan Railway Company 35,679 26 8001 ITOCHU Corporation 35,541 27 8766 Tokio Marine Holdings,Inc. 35,145 28 7741 HOYA CORPORATION 34,808 29 6594 NIDEC CORPORATION 33,433 30 8035 Tokyo Electron Limited 32,000 31 3382 Seven & I Holdings Co.,Ltd. 31,699 32 7751 CANON INC. 31,463 33 8411 Mizuho Financial Group,Inc.